Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Veracyte, Inc. before investing.

In this article, we go over a few key elements for understanding Veracyte, Inc.’s stock price such as:

• Veracyte, Inc.’s current stock price and volume
• Why Veracyte, Inc.’s stock price changed recently
• Upgrades and downgrades for VCYT from analysts
• VCYT’s stock price momentum as measured by its relative strength

About Veracyte, Inc. (VCYT)

Before we jump into Veracyte, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Want to learn more about Veracyte, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Veracyte, Inc..

Veracyte, Inc.’s Stock Price as of Market Close

As of August 21, 2026, 11:45 AM, CST, Veracyte, Inc.’s stock price was $42.245.

Veracyte, Inc. is up 1.09% from its previous closing price of $41.790.

During the last market session, Veracyte, Inc.’s stock traded between $41.100 and $42.410. Currently, there are approximately 79.97 million shares outstanding for Veracyte, Inc..

Veracyte, Inc.’s price-earnings (P/E) ratio is currently at 30.0, which is high compared to the Biotechnology industry median of 19.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Veracyte, Inc. Stock Price History

Veracyte, Inc.’s (VCYT) price is currently down 8.8% so far this month.

During the month of August, Veracyte, Inc.’s stock price has reached a high of $47.960 and a low of $40.095.

Over the last year, Veracyte, Inc. has hit prices as high as $60.910 and as low as $28.250. Year to date, Veracyte, Inc.’s stock is up 0.34%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Veracyte, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 20, 2026, there were 0 analysts who downgraded Veracyte, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Veracyte, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Veracyte, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Veracyte, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Veracyte, Inc. (VCYT) by visiting AAII Stock Evaluator.

Relative Price Strength of Veracyte, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 20, 2026, Veracyte, Inc. has a weighted four-quarter relative price strength of 2.58%, which translates to a Momentum Score of 61 and is considered to be Strong.

Want to learn more about how Veracyte, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Veracyte, Inc. Stock Price: Bottom Line

As of August 21, 2026, Veracyte, Inc.’s stock price is $42.245, which is up 1.09% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Veracyte, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.